Frazier Life Sciences Management, L.P.
Frazier Life Sciences Management, L.P. reported 44 holdings worth US$4.03B as of Sep 30, 2026 (Form 13F)
As of Sep 30, 2026 · Filed Nov 16, 2026
Frazier Life Sciences Management, L.P. reported 44 holdings worth US$4.03B as of Sep 30, 2026. Largest: Mirum Pharmaceuticals, Inc., Erasca, Inc. and MBX Biosciences, Inc. Filed Nov 16, 2026 (Form 13F).
- Holdings
- 44
- Value as reported
- US$4.03B
The filing in full
| Company | Shares | Value as reported | % of portfolio |
|---|
| Mirum Pharmaceuticals, Inc. | 7.68M | US$656M | 16.3% |
| Erasca, Inc. | 29.5M | US$432M | 10.7% |
| MBX Biosciences, Inc. | 6.65M | US$390M | 9.7% |
| Arcutis Biotherapeutics, Inc. | 9.87M | US$261M | 6.5% |
| Maze Therapeutics, Inc. | 5.28M | US$144M | 3.6% |
| Trevi Therapeutics, Inc. | 9.54M | US$137M | 3.4% |
| Krystal Biotech, Inc. | 391K | US$130M | 3.2% |
| Palvella Therapeutics, Inc. | 882K | US$122M | 3.0% |
| Attovia Therapeutics, Inc. | 7.05M | US$121M | 3.0% |
| Braveheart Bio, Inc. | 5.27M | US$106M | 2.6% |
| Phathom Pharmaceuticals, Inc. | 12.5M | US$91M | 2.3% |
| Parabilis Medicines, Inc. | 2.33M | US$75.3M | 1.9% |
| Dyne Therapeutics, Inc. | 3.85M | US$62.1M | 1.5% |
| Achieve Life Sciences, Inc. | 7.61M | US$61.6M | 1.5% |
| MannKind Corporation | 15.8M | US$61.4M | 1.5% |
| Disc Medicine, Inc. | 935K | US$61.2M | 1.5% |
| Tarsus Pharmaceuticals, Inc. | 720K | US$56.6M | 1.4% |
| Vor Biopharma Inc. | 2.74M | US$52.4M | 1.3% |
| Zai Lab Ltd. | 1.9M | US$50.1M | 1.2% |
| Aclaris Therapeutics, Inc. | 8.73M | US$45.9M | 1.1% |
| Aura Biosciences, Inc. | 7.1M | US$44.6M | 1.1% |
| Allogene Therapeutics, Inc. | 22.4M | US$35.9M | 0.89% |
| BioCryst Pharmaceuticals, Inc. | 4.01M | US$33.4M | 0.83% |
| Celldex Therapeutics, Inc. | 900K | US$29.2M | 0.72% |
| ACADIA Pharmaceuticals Inc. | 1.44M | US$29M | 0.72% |
| Shattuck Labs, Inc. | 3.75M | US$25.6M | 0.63% |
| Immunocore Holdings plc | 830K | US$25.1M | 0.62% |
| Design Therapeutics, Inc. | 1.81M | US$22.7M | 0.56% |
| Evolus, Inc. Common Stock | 2.63M | US$21M | 0.52% |
| Sarepta Therapeutics, Inc. | 1.07M | US$19.5M | 0.48% |
| Relay Therapeutics, Inc. | 1.02M | US$18.3M | 0.45% |
| Lexeo Therapeutics, Inc. | 4.82M | US$16.3M | 0.40% |
| Valneva SE | 2.29M | US$14.2M | 0.35% |
| Kailera Therapeutics, Inc. | 1.2M | US$13.7M | 0.34% |
| Monte Rosa Therapeutics, Inc. | 1M | US$11.9M | 0.30% |
| ORIC Pharmaceuticals, Inc. | 752K | US$10.1M | 0.25% |
| Autolus Therapeutics plc | 4.45M | US$8.63M | 0.21% |
| Savara, Inc. | 1.11M | US$5.75M | 0.14% |
| Xilio Therapeutics, Inc. | 423K | US$3.82M | 0.09% |
| TCGX Acquisition Corp. | 300K | US$3.75M | 0.09% |
| iBio, Inc. | 1.95M | US$2.31M | 0.06% |
| Ascendis Pharma A/S | 0 | US$0 | 0.00% |
| BridgeBio Pharma, Inc. | 0 | US$0 | 0.00% |
| Cytokinetics, Incorporated | 0 | US$0 | 0.00% |
Source
Download original · View original at SEC
Related